Monday
14:30-17:00
Heubner Hall

Focus on the Future: Latest Scientific and Clinical Understanding for the Treatment of Patients with Type 2 Diabetes

Afternoon Session

Steven Kahn (USA), Lawrence Leiter (Canada)
Chair Welcome and Opening Remarks
Jonathan Campbell (USA)
Scientific Spotlight #1: Recent Advancements in the Alpha Cell and the Beta Cell
Juan Frias (USA)
Shedding New Light on Clinical Questions: The COMPOSIT Trials
Steven Kahn (USA), Lawrence Leiter (Canada), Faculty
Clinical Applications- Part 1
Sam Dagogo-Jack (USA)
Ertugliflozin – A Newly Emerging SGLT2 Inhibitor for Patients with Type 2 Diabetes
Matthew Cavender (USA)
Envisioning the Future of SGLT2 Inhibitors in the Treatment of Patients with Diabetes and Established Cardiovascular Disease: A Cardiologist Viewpoint
Steven Kahn (USA), Lawrence Leiter (Canada), Faculty
Clinical Applications- Part 2
Michael Nauck (Germany)
Keynote: SGLT2 Inhibitors: DPP-4 Inhibitors and SGLT2 Inhibitors: Is There Something Special About These Mechanisms?
Steven Kahn (USA), Lawrence Leiter (Canada)
Final Comments and Summary
Symposia by: